Latest Posts

30

May 24

Partex and Singapore’s Experimental Drug Development Centre collaborate to bring forward an innovative approach for early drug discovery and development

Frankfurt, Germany, 3rd June 2024, 9am CET Partex, a leading provider of AI-driven solutions in the pharmaceutical industry, is thrilled...
Read More

22

Apr 24

Partex Partners with Lupin to Revolutionize Drug Discovery through AI-Driven Asset Search and Evaluation

Frankfurt, Germany, 23 April 2024 – Partex, a leading provider of AI-driven solutions in the pharmaceutical industry, is thrilled to...
Read More

Innoplexus wins Horizon Interactive Gold Award for Curia App

Read More
Try Ontosight® For Free

Why we are?

On the way to a Global Artificial Intelligence Champ

When we looked at the decision making landscape in organizations and observed that the available technologies and models were helping make decisions but with fixed cycles of information processing, running in batches, with little flexibility and agility.

Drug development process is...

Slow
~85%
from drug discovery to approval
Inefficient
~85%
of biomdical research is wasted
Risky
~90%
risk of failure in clinical trials

Key data challenges are...

Accessibility
Data is hidden in silos within organization
Ownership
Patients have no stake in use of their data
Insights
Pharma, Biotechs fail to access valuable healthcare data

How blockchain and AI can help us decipher medicine's big data

This video originally published on TED.

Mission & Vision

Mission

“Empowering our customers and partners with AI to develop newer, more efficacious therapies faster.”

Vision

“Building a universal treatment discovery engine for the untreatable diseases.”

Team Overview

Interdisciplinary Team

90

Data
Scientists

90

Software
Engineers

55%

Female

110

Medical
Experts

7

Commercial

45%

Male

Leadership Team

Dr. Gunjan Bhardwaj

Founder

Gunjan is the Founder of Innoplexus and led the company as its CEO until 31st October 2022. He is an adjunct professor at Frankfurt School of Finance and management and Pforzheim University, Germany. He is an Ex BCG, EY who studied at IIT Bombay, MIT, Pforzheim University and European Business School. He has 18+ patents related to AI & Blockchain.

He published 2 books in Branding and Drug Discovery respectively as well as a number of publications in Harvard Business Review, Journal of Service Research, MIT Sloan Review etc. He received several awards including Capital – 40 under 40 award for Young Elite Award, Handelsblatt – BCG “Future Leaders of the new Reality“ and Top 30 “Thought Leader“ Award, Germany.

Gaurav Tripathi

Co-Founder, Group CTO

Gaurav Tripathi is a serial entrepreneur, co-founder, Group CTO, and Member of the Executive Board at Innoplexus AG and Board Member at Amrit AG

He studied at IIT Bombay and has 18+ years of experience across multiple startups working in Video, Big Data, Blockchain, and AI. He co-founded Innoplexus, now known as the “German AI champion in Life Sciences” working with top 30 Pharma companies globally. As Group CTO, he led the team to build an IP portfolio of 145+ patents (US/EU) in areas around AI, out of which 45 have him as an inventor.

Gaurav enjoys trekking, traveling, reading, and mentoring aspiring entrepreneurs and emerging startups.

Holger Hoffmann

Director

Holger Hoffmann brings with him over 25 years of broad international experience in Sales, Finance, Controlling, Joint Ventures, M&A, and Operations within management holdings, family-owned companies, and large industrial corporations.

Holger has the rare combination of experience in finance and sales, and due to his multilingual capability and genuine interest in diverse cultures he has developed excellent global business relationships.

Prof. Dr. Dr. Juergen Scheele

Chief Medical Officer

Prof. Dr. Dr. Juergen Scheele is the 
Chief Medical Officer at Innoplexus and SVP Drug Development. He brings in over 20+ years of expertise in drug development and discovery. Prior to joining Innoplexus, Jürgen has held various senior positions such as Merck Global Clinical Development Leader for Tepotinib and other molecules, Global Development Leader at Roche Basel and Medical Director Micromet/ Amgen.

Jürgen has an extensive research background having received a PhD in Biochemistry / Molecular Biology from UC San Diego and the Salk Institute as well as a Master of Science in Chemistry from UC San Diego.

Dr. med. Werner Seiz

SVP – Translational Science

Werner is the SVP – Translational Science at Innoplexus. He brings more than 28 years of expertise, primarily in early stage clinical development, biomarkers, bioimaging and drug safety evaluation.

His key expertise lies in clinical and pre-clinical studies for autoimmune diseases, cardiovascular, respiratory and renal indications as well as all kinds of ligand-binding assay development, validation and application.

Werner is an MD from Goethe University, Germany.

Amit Ananpara

Managing Director

Seasoned Professional with over 20 years in Project Management, Business Analysis, Strategy and Delivery. Experience in both US and Indian Markets.

Ex Infosys, LTI, Allstate, Liberty Mutual Insurance.

Studied at University of Mumbai

Supervisory Board

Ruben King-Shaw Jr.

Chairman, Supervisory Board

Ruben King-Shaw Jr. has over three decades of executive leadership experience in the healthcare technology and private equity sectors and has held C-suite positions with leading private companies. He is a Chief Strategy Officer and Member of the Executive Committee of the Board of Steward Health, LLC since 2018. He is also a Chief executive officer of Mansa Equity Partners, Inc., a private equity and investment advisory firm specializing in supporting the growth of healthcare companies.

Mr. King-Shaw served on the Obama Administration’s Medicare Program Advisory and Oversight Committee.

Mohan Murti

Attorney & Counselor at Law

Accomplished leader with over 40 years of successful experience in global business management. Demonstrated ability of revenue generation while promoting business strategy on an international basis – largely based in Europe.

Initially, nominated by the Ministry of Commerce, Government of India as India’s Representative to UNITED NATIONS-IPS, Paris and Zurich and since 1993, Director, Europe, CII, Cologne, Germany. Since 2004, Managing Director, Europe, Reliance Europe. Leadership Coach & Cross-Cultural Trainer noted for establishing team synergies.

Ranjeetsinh Jayendra Pawar

Advocate and Legal Advisor

Ranjeet, an alumnus of the prestigious ILS Law College Pune, established a Pune-based corporate law practice known for global standards. Specializing in business disputes, real estate, and investment transactions, he is the preferred counsel for Tier-1 law firms and large corporations in Pune. Known for his practical solutions, Ranjeet handles high-profile investigations, including disciplinary actions, data breaches and corporate criminality issues. His passion for mentoring start-ups shows through successful funding transactions and incubation efforts. He is a Partner at SRB-OJAS, one of the most renowned law firms in Pune. Advising Innoplexus for a decade, his privacy and healthcare law expertise drives positive change through social impact projects, particularly in rural healthcare.

Jayant Bhatt

Masters of Law (LL.M.)

Mr. Bhatt holds dual Masters of Law (LL.M.)from New York University, USA & National University of Singapore and is a member of the prestigious Supreme Court Bar Association and Delhi High Court Bar Association. His office caters to varied clients comprising Governmental and Non-Governmental Bodies, Multinationals, Financial Institutions and individuals in an array of matters.

Mr Bhatt besides being a practicing Advocate is also a prolific speaker at various platforms and is an individual with firm belief in greater societal good. He has a keen interest in teaching and mentoring young minds and is an advisory board member to various organizations.